BMY's Quality Score fell 3 points on Tue, Nov 10, to 11.
Follow BMY's trial news. Pro members can get an alert when Bristol-Myers Squibb files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 1% on Oct 29, and still 3% over its Oct 28 close.
“Revenue growth was primarily driven by Opdivo Qvantig , Breyanzi , Reblozyl, Camzyos and Opdualag.”
| The chart | Above a rising 200-day average |
| Latest filing | 8-K, Oct 29 |
BMY closed −2.6% that day on 2.0x normal volume.
Wed Nov 11: BioPharma Cell & Gene Therapy Nexus 2026Industry event · date confirmed.
Expected to report Thu Feb 4, before the open
Director Julia A. Haller sold 3,800 shares on Nov 5. 3 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Above Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
BMY is #20 of 90 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 20 |
Net income over four quarters: BMY $9.24B, LLY $27.6B, JNJ $16.1B, REGN $4.82B.
Expected to report Thu Feb 4, before the open (in 86 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $13.1B, 7% more than a year ago.
“This update primarily reflects broad-based and continuing momentum across the portfolio.”
| Line | Q3 2026 | Q2 2026 | Q3 2025 |
|---|---|---|---|
| Sales Revenue, Gross | $18B | $18B | $22B |
Each quarter's sales and their share of its total. Figures as filed (SEC filing, Oct 29)
| Measure | Figure |
|---|---|
| Full-year non-GAAP revenue | about $49.75B to $50.25B |
“Gross margin decreased from 71.9% to 68.3% on a GAAP basis, and from 72.9% to 68.4% on a non-GAAP basis, primarily reflecting a change in product mix and, to a lesser extent, a one-time charge related to a contract termination in 2026.”
From its results filing (SEC filing · Oct 29)
Sales grew 2.5% a year over 5 years, fiscal 2020 to 2025.
Pays $2.52 a share a year.
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Oct 29, 2026 | +0.7% | +1.4% | +6.0% |
| Jul 30, 2026 | -0.7% | +2.8% | +0.8% |
| Apr 30, 2026 | +0.2% | +5.2% | -1.7% |
Sales grew in four of the last seven years, to $48B in 2025. It turned a profit in 2025 after a loss in 2024.
RSI 49.9, MACD above signal, below its 50-day, above its 200-day. Not scored.
Its dividends come to 56% of its free cash flow.
| Dividend | $2.52 a share a year |
| Paid out | About $5.2B a year |
| Free cash flow | $9.3B |
| Record | Raised every year since 2007 |
3 insiders sold $678K across 3 filings in the last 6 months. No open-market buys on record. The newest:
14 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: BMY is 3.0% of SCHD, 1.3% of JEPI, and 0.5% of VYM, the most of the 24 funds Breakaway covers, by each fund's latest filing, Jun 30 to Aug 31, 2026.
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
“The markets in which we compete are generally broad-based and highly competitive.”
BMY scores 11 today, which Breakaway calls Above Average. It is #20 of 90 in Pharma by Quality Score, with 4 of 14 chart checks firing. Up 1% on Oct 29, and still 3% over its Oct 28 close. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
BMY scores 11 today, which Breakaway calls Above Average (11 to 14). That is #20 of 90 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind BMY's 11.
3 insiders sold $678K across 3 filings in the last 6 months. No open-market buys on record. The newest is Julia A. Haller, Director, who sold $241K on Nov 5. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free for 24 hours. No account. No card. Then keep going with a free account.